دورية أكاديمية
Percutaneous ethanol injection is an acceptable bridging therapy to hepatocellular carcinoma prior to liver transplantation.
العنوان: | Percutaneous ethanol injection is an acceptable bridging therapy to hepatocellular carcinoma prior to liver transplantation. |
---|---|
المؤلفون: | Lazzarotto-da-Silva G; Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clínicas de Porto Alegre, Medical School of UFRGS, Rua Ramiro Barcelos 2350, Sixth Floor, Room 600, Porto Alegre, 91340-400, Brazil., Grezzana-Filho TJM; Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clínicas de Porto Alegre, Medical School of UFRGS, Rua Ramiro Barcelos 2350, Sixth Floor, Room 600, Porto Alegre, 91340-400, Brazil., Scaffaro LA; Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clínicas de Porto Alegre, Medical School of UFRGS, Rua Ramiro Barcelos 2350, Sixth Floor, Room 600, Porto Alegre, 91340-400, Brazil., Farenzena M; Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clínicas de Porto Alegre, Medical School of UFRGS, Rua Ramiro Barcelos 2350, Sixth Floor, Room 600, Porto Alegre, 91340-400, Brazil., Silva RK; Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clínicas de Porto Alegre, Medical School of UFRGS, Rua Ramiro Barcelos 2350, Sixth Floor, Room 600, Porto Alegre, 91340-400, Brazil., de Araujo A; Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clínicas de Porto Alegre, Medical School of UFRGS, Rua Ramiro Barcelos 2350, Sixth Floor, Room 600, Porto Alegre, 91340-400, Brazil., Arruda S; Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clínicas de Porto Alegre, Medical School of UFRGS, Rua Ramiro Barcelos 2350, Sixth Floor, Room 600, Porto Alegre, 91340-400, Brazil., Feier FH; Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clínicas de Porto Alegre, Medical School of UFRGS, Rua Ramiro Barcelos 2350, Sixth Floor, Room 600, Porto Alegre, 91340-400, Brazil., Prediger L; Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clínicas de Porto Alegre, Medical School of UFRGS, Rua Ramiro Barcelos 2350, Sixth Floor, Room 600, Porto Alegre, 91340-400, Brazil., Lazzaretti GS; Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clínicas de Porto Alegre, Medical School of UFRGS, Rua Ramiro Barcelos 2350, Sixth Floor, Room 600, Porto Alegre, 91340-400, Brazil., Alvares-da-Silva MR; Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clínicas de Porto Alegre, Medical School of UFRGS, Rua Ramiro Barcelos 2350, Sixth Floor, Room 600, Porto Alegre, 91340-400, Brazil., Chedid AD; Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clínicas de Porto Alegre, Medical School of UFRGS, Rua Ramiro Barcelos 2350, Sixth Floor, Room 600, Porto Alegre, 91340-400, Brazil., Kruel CRP; Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clínicas de Porto Alegre, Medical School of UFRGS, Rua Ramiro Barcelos 2350, Sixth Floor, Room 600, Porto Alegre, 91340-400, Brazil., Chedid MF; Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clínicas de Porto Alegre, Medical School of UFRGS, Rua Ramiro Barcelos 2350, Sixth Floor, Room 600, Porto Alegre, 91340-400, Brazil. marciochedid@hotmail.com. |
المصدر: | Langenbeck's archives of surgery [Langenbecks Arch Surg] 2023 Jan 14; Vol. 408 (1), pp. 26. Date of Electronic Publication: 2023 Jan 14. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 9808285 Publication Model: Electronic Cited Medium: Internet ISSN: 1435-2451 (Electronic) Linking ISSN: 14352443 NLM ISO Abbreviation: Langenbecks Arch Surg Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Berlin : Springer-Verlag, c1998- |
مواضيع طبية MeSH: | Carcinoma, Hepatocellular*/surgery , Liver Neoplasms*/surgery , Liver Transplantation* , Chemoembolization, Therapeutic*/adverse effects , Catheter Ablation*, Humans ; Ethanol ; Treatment Outcome ; Retrospective Studies |
مستخلص: | Purpose: Locoregional therapies (LRT) are employed for bridging patients with hepatocellular carcinoma (HCC) awaiting orthotopic liver transplantation (OLT). Although the main LRT options include transarterial chemoembolization (TACE) and radiofrequency ablation (RFA), percutaneous ethanol injection (PEI) is an alternative with considerably lower costs. This study is a pioneering evaluation of the natural history of PEI bridging to OLT as compared to TACE. Methods: All consecutive cirrhotic patients with HCC enlisted for OLT (2011-2020) at a single center were analyzed. Patients were divided into three LRT modality groups: PEI, TACE, and PEI+TACE. The primary study outcome was waitlist dropout due to tumor progression beyond Milan criteria. A comparison of post-transplant outcomes of patients as stratified by LRT modality also was performed. Results: One hundred twenty-nine patients were included (PEI=56, TACE=43, PEI+TACE=30). The dropout rate due to tumor progression was not different among the three groups: PEI=8.9%, TACE=14%, PEI+TACE=16.7% (p=0.54). Thirteen (76.4%) patients underwent OLT after successful downstaging (3 [75%] in the PEI group, 5 [83.3%] in the TACE group, and 5 [71.4%] in the PEI+TACE group). For the 96 patients undergoing OLT, 5-year post-transplant recurrence-free survival was PEI=55.6% vs. TACE=55.1% vs. PEI+TACE=71.4% (p=0.42). Complete/near-complete pathological response rate was similar among groups (p=0.82). Conclusion: Dropout rates and post-transplant recurrence-free survivals related to PEI were comparable to those of TACE. This study supports the use of PEI alone or in combination with TACE for HCC patients awaiting OLT whenever RFA is not an option. (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.) |
التعليقات: | Erratum in: Langenbecks Arch Surg. 2023 Feb 16;408(1):92. (PMID: 36792843) |
References: | Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today , Accessed 13 January 2022. El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365:1118–1127. (PMID: 21992124) Ebara M, Hatano R, Fukuda H, Yoshikawa M, Sugiura N, Saisho H (1998) Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 32 patients. Hepatogastroenterology 45(Suppl 3):1214–1220. (PMID: 9730377) Chedid AD, Klein PW, Tiburi MF, Villwock MM, Bassani LE, Chedid MF (2001) Spontaneous rupture of hepatocellular carcinoma with haemoperitoneum: a rare condition in Western countries. HPB 3:227–230. (PMID: 183330202020622) Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907–1917. (PMID: 14667750) Reig M, Forner A, Rimola J et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 76(3):681–693. Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699. (PMID: 8594428) Heimbach JK, Hirose R, Stock PG et al (2015) Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States. Hepatology 61:1643–1650. (PMID: 25644186) Arruda S, Chedid MF, Jacinto MM, Álvares-DA-Silva MR (2020) Meld exception points provide an enourmous advantage for receiving a liver transplant in brazil. Arq Gastroenterol 57(3):254–2611. (PMID: 32935744) Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A (2012) OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 13:e11–e22. (PMID: 22047762) Kulik L, Heimbach JK, Zaiem F et al (2018) Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology 67:381–400. (PMID: 28859222) Pompili M, Mirante VG, Rondinara G et al (2005) Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 11:1117–1126. (PMID: 16123960) Trotter JF (2017) Liver transplantation around the world. Curr Opin Organ Transplant 22:123–127. (PMID: 28151809) Bittencourt PL, Farias AQ, Couto CA (2016) Liver Transplantation in Brazil. Liver Transpl 22:1254–1258. (PMID: 27228568) Huo TI, Huang YH, Su CW et al (2008) Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy. Clin Transplant 22:469–475. (PMID: 18318736) Chedid MF, Scaffaro LA, Chedid AD et al (2016) Transarterial embolization and percutaneous ethanol injection as an effective bridge therapy before liver transplantation for hepatitis C-related hepatocellular carcinoma. Gastroenterol Res Pract 2016:9420274. (PMID: 26819615) Lee YT, Wang JJ, Zhu Y, Agopian VG, Tseng HR, Yang JD (2021) Diagnostic criteria and LI-RADS for hepatocellular carcinoma. Clin Liver Dis 17(6):409–413. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC (2000) A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31:864–871. (PMID: 10733541) Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213. (PMID: 152735421360123) R Core Team (2020) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. Castroagudin JF, Delgado M, Martinez SM et al (2005) Prospective histopathological analysis of hepatocellular carcinoma treated with percutaneous ethanol injection in patients on the waiting list for liver transplantation. Transplant Proc 37:1477–1479. (PMID: 15866645) Branco F, Brú C, Vilana R, Bianchi L, Alves de Mattos A (2009) Percutaneous ethanol injection before liver transplantation in the hepatocellular carcinoma. Ann Hepatol 8:220–227. (PMID: 19841501) Chapman WC, Majella Doyle MB, Stuart JE et al (2008) Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 248:617–625. (PMID: 18936575) Shi F, Wu M, Lian SS et al (2019) Radiofrequency ablation following downstaging of hepatocellular carcinoma by using transarterial chemoembolization: long-term outcomes. Radiology 293:707–715. (PMID: 31638492) Yao FY, Mehta N, Flemming J et al (2015) Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 61:1968–1977. (PMID: 25689978) Cillo U, Vitale A, Grigoletto F et al (2007) Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria. Am J Transplant 7:972–981. (PMID: 17391137) Ravaioli M, Grazi GL, Piscaglia F et al (2008) Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 8:2547–2557. (PMID: 19032223) Brunello F, Veltri A, Carucci P et al (2008) Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 43(6):727–735. (PMID: 18569991) Mehta N, Dodge JL, Roberts JP, Yao FY (2021) A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival. J Hepatol 74:829–837. (PMID: 33188904) Seehofer D, Nebrig M, Denecke T et al (2012) Impact of neoadjuvant transarterial chemoembolization on tumor recurrence and patient survival after liver transplantation for hepatocellular carcinoma: a retrospective analysis. Clin Transplant 26:764–774. (PMID: 22432589) Agopian VG, Morshedi MM, McWilliams J et al (2015) Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients. Ann Surg 262:536–545. (PMID: 26258323) Chedid MF (2017) Nonalcoholic steatohepatitis: the second leading indication for liver transplantation in the USA. Dig Dis Sci 62:2621–2622. (PMID: 28840385) Cholankeril G, Wong RJ, Hu M, Perumpail RB, Yoo ER, Puri P, Younossi ZM, Harrison SA, Ahmed A (2017) Liver Transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes. Dig Dis Sci 62:2915–2922. (PMID: 28744836) Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67(1):358–380. (PMID: 28130846) |
فهرسة مساهمة: | Keywords: Hepatocellular carcinoma; Liver transplant; Locoregional therapy; Percutaneous ethanol injection |
المشرفين على المادة: | 3K9958V90M (Ethanol) |
تواريخ الأحداث: | Date Created: 20230113 Date Completed: 20230117 Latest Revision: 20240118 |
رمز التحديث: | 20240118 |
DOI: | 10.1007/s00423-022-02750-y |
PMID: | 36639606 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1435-2451 |
---|---|
DOI: | 10.1007/s00423-022-02750-y |